IMRX - Immuneering Corp

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 1.63

Open

$ 1.60

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 1.56 - $ 1.70

52 Week Range

$ 1.38 - $ 11.92

Volume

256,779

Average Volume

Market Cap

47.87M

Beta (5Y Monthly)

$ 0.75

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	03-01-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-06-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-10-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-10-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	09-09-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Immuneering, Mai...
05/08/2024 09:58:36

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.

Immuneering Q1 EPS $(0.49) Misses $(0.46) ...
05/07/2024 21:02:15

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.46)...

Needham Reiterates Buy on Immuneering, Mai...
04/12/2024 10:33:08

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.

Immuneering Presented Preclinical Data At ...
04/09/2024 16:04:39

Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatme...

Immuneering Announces First Patient Dosed ...
03/27/2024 12:08:00

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mu...

why-science-applications-international-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Science Applications International Sha...
03/18/2024 18:37:43

Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company r...

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
03/18/2024 17:31:33

cancer-treatment-focused-immuneering-faces-analyst-downgrades-who-cite-underwhelming-solid-tumor-trial-data

Cancer Treatment Focused Immuneering Faces...
03/15/2024 19:29:25

Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues des...

dow-falls-over-200-points-adobe-shares-plunge

Dow Falls Over 200 Points; Adobe Shares Pl...
03/15/2024 18:40:28

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded...

Why Jabil Shares Are Trading Lower By Over...
03/15/2024 18:31:53

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter resu...

12-health-care-stocks-moving-in-fridays-intraday-session

12 Health Care Stocks Moving In Friday's I...
03/15/2024 17:31:09

crude-oil-edges-lower-us-consumer-sentiment-falls-in-march

Crude Oil Edges Lower; US Consumer Sentime...
03/15/2024 16:05:34

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded do...

Jefferies Downgrades Immuneering to Hold, ...
03/15/2024 12:16:17

Jefferies analyst Michael Yee downgrades Immuneering (NASDAQ:IMRX) from Buy to Hold and lowers the price target from $16 to $3.

Chardan Capital Maintains Buy on Immuneeri...
03/15/2024 11:20:09

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and lowers the price target from $21 ...

Needham Maintains Buy on Immuneering, Lowe...
03/15/2024 10:54:29

Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and lowers the price target from $20 to $15.

TD Cowen Downgrades Immuneering to Market ...
03/15/2024 08:52:02

TD Cowen analyst Yaron Werber downgrades Immuneering (NASDAQ:IMRX) from Outperform to Market Perform.

Guggenheim Downgrades Immuneering to Neutral
03/14/2024 20:09:10

Guggenheim analyst Michael Schmidt downgrades Immuneering (NASDAQ:IMRX) from Buy to Neutral.

why-limbach-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why Limbach Holdings Shares Are Trading Lo...
03/14/2024 17:38:41

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...

12-health-care-stocks-moving-in-thursdays-intraday-session

12 Health Care Stocks Moving In Thursday's...
03/14/2024 17:31:16

whats-going-on-with-cancer-focused-immuneering-stock-on-thursday

What's Going On With Cancer-Focused Immune...
03/14/2024 16:36:55

Unlock the latest Phase 1 trial results for IMM-1-104 by Immuneering. Discover how 320mg and 240mg doses inhibit tumor progress...